Lumos Pharma Stock Short Ratio
| LUMO Stock | USD 3.02 0.02 0.67% |
Lumos Pharma fundamentals help investors to digest information that contributes to Lumos Pharma's financial success or failures. It also enables traders to predict the movement of Lumos Stock. The fundamental analysis module provides a way to measure Lumos Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lumos Pharma stock.
Lumos | Short Ratio |
Lumos Pharma Company Short Ratio Analysis
Lumos Pharma's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Lumos Pharma Short Ratio | 22.28 X |
Most of Lumos Pharma's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lumos Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lumos Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Lumos Pharma is extremely important. It helps to project a fair market value of Lumos Stock properly, considering its historical fundamentals such as Short Ratio. Since Lumos Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lumos Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lumos Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Lumos Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Lumos Pharma has a Short Ratio of 22.28 times. This is much higher than that of the Biotechnology sector and 200.67% higher than that of the Health Care industry. The short ratio for all United States stocks is notably lower than that of the firm.
Lumos Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lumos Pharma's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lumos Pharma could also be used in its relative valuation, which is a method of valuing Lumos Pharma by comparing valuation metrics of similar companies.Lumos Pharma is currently under evaluation in short ratio category among related companies.
Lumos Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lumos Pharma from analyzing Lumos Pharma's financial statements. These drivers represent accounts that assess Lumos Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lumos Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 366.1K | 242.0M | 57.8M | 30.2M | 25.9M | 39.6M | |
| Enterprise Value | (89.0M) | 143.7M | (36.5M) | (25.5M) | (2.6M) | (2.7M) |
Lumos Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Lumos Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lumos Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lumos Pharma's value.| Shares | Blackrock Inc | 2023-12-31 | 43.5 K | Two Sigma Investments Llc | 2023-12-31 | 42.6 K | Two Sigma Advisers, Llc | 2023-12-31 | 28.3 K | Marquette Asset Management Inc. | 2023-12-31 | 25.8 K | Private Advisor Group, Llc | 2023-12-31 | 16 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 15.6 K | Envestnet Asset Management Inc | 2023-12-31 | 11.9 K | Bank Of New York Mellon Corp | 2023-12-31 | 11.9 K | Wealth Advisors Of Iowa, Llc | 2023-12-31 | 11.7 K | Goldman Sachs Group Inc | 2023-12-31 | 813.2 K | Wells Fargo & Co | 2023-12-31 | 417.1 K |
Lumos Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.41 | ||||
| Operating Margin | (12.11) % | ||||
| Current Valuation | (11.17 M) | ||||
| Shares Outstanding | 8.12 M | ||||
| Shares Owned By Insiders | 34.83 % | ||||
| Shares Owned By Institutions | 29.30 % | ||||
| Number Of Shares Shorted | 286.92 K | ||||
| Price To Earning | (2.37) X | ||||
| Price To Book | 0.78 X | ||||
| Price To Sales | 10.44 X | ||||
| Revenue | 2.05 M | ||||
| Gross Profit | 1.52 M | ||||
| EBITDA | (36.57 M) | ||||
| Net Income | (34.03 M) | ||||
| Cash And Equivalents | 79.51 M | ||||
| Cash Per Share | 9.49 X | ||||
| Total Debt | 6.58 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 17.59 X | ||||
| Book Value Per Share | 4.48 X | ||||
| Cash Flow From Operations | (31.09 M) | ||||
| Short Ratio | 22.28 X | ||||
| Earnings Per Share | (4.18) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 22.5 | ||||
| Number Of Employees | 33 | ||||
| Beta | 0.35 | ||||
| Market Capitalization | 24.35 M | ||||
| Total Asset | 40.64 M | ||||
| Retained Earnings | (161.52 M) | ||||
| Working Capital | 33.01 M | ||||
| Current Asset | 115.78 M | ||||
| Current Liabilities | 14.4 M | ||||
| Net Asset | 40.64 M |
About Lumos Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lumos Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lumos Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lumos Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lumos Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lumos Pharma's short interest history, or implied volatility extrapolated from Lumos Pharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Lumos Pharma Piotroski F Score and Lumos Pharma Altman Z Score analysis. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Lumos Stock analysis
When running Lumos Pharma's price analysis, check to measure Lumos Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lumos Pharma is operating at the current time. Most of Lumos Pharma's value examination focuses on studying past and present price action to predict the probability of Lumos Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lumos Pharma's price. Additionally, you may evaluate how the addition of Lumos Pharma to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Lumos Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.18) | Revenue Per Share 0.252 | Quarterly Revenue Growth 0.613 | Return On Assets (0.41) | Return On Equity (0.78) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.